COMPASS PATHWAYS PLC (CMPS) Stock Price & Overview
NASDAQ:CMPS • US20451W1018
Current stock price
The current stock price of CMPS is 5.79 USD. Today CMPS is up by 3.02%. In the past month the price decreased by -14.54%. In the past year, price increased by 113.65%.
CMPS Key Statistics
- Market Cap
- 657.263M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -2.86
- Dividend Yield
- N/A
CMPS Stock Performance
CMPS Stock Chart
CMPS Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to CMPS. When comparing the yearly performance of all stocks, CMPS is one of the better performing stocks in the market, outperforming 89.36% of all stocks.
CMPS Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to CMPS. Both the profitability and financial health of CMPS have multiple concerns.
CMPS Earnings
CMPS Forecast & Estimates
17 analysts have analysed CMPS and the average price target is 23.77 USD. This implies a price increase of 310.47% is expected in the next year compared to the current price of 5.79.
CMPS Groups
Sector & Classification
CMPS Financial Highlights
Over the last trailing twelve months CMPS reported a non-GAAP Earnings per Share(EPS) of -2.86. The EPS decreased by -30% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -92.84% | ||
| ROE | -631.31% | ||
| Debt/Equity | 0.49 |
CMPS Ownership
CMPS Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.07 | 369.265B | ||
| AMGN | AMGEN INC | 15.24 | 187.564B | ||
| GILD | GILEAD SCIENCES INC | 15.81 | 173.439B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.63 | 111.445B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.3 | 80.543B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 42.73 | 42.286B | ||
| INSM | INSMED INC | N/A | 35.012B | ||
| NTRA | NATERA INC | N/A | 29.477B | ||
| BIIB | BIOGEN INC | 11.03 | 26.026B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.91 | 24.756B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.643B | ||
| MRNA | MODERNA INC | N/A | 19.431B | ||
| INCY | INCYTE CORP | 12.53 | 19.091B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About CMPS
Company Profile
Compass Pathways Plc is a biotechnology company, which provides mental health care services. The company is headquartered in Altrincham, Cheshire and currently employs 166 full-time employees. The company went IPO on 2020-09-18. The firm is engaged in treating mental health conditions focused on rapid and durable responses through the development of its investigational COMP360 psilocybin treatment. COMP360 is its psilocybin formulation that includes its pharmaceutical-grade polymorphic crystalline psilocybin, optimized for stability and purity. The Company’s initial focus is on treatment-resistant depression (TRD), comprising patients who are inadequately served by the current treatment paradigm. The company commenced its Phase III program evaluating its COMP360 psilocybin treatment in TRD. In addition, the Company has ongoing Phase II trials in PTSD and anorexia nervosa. The company also provides support to research institutions conducting investigator-initiated studies with COMP360 psilocybin in areas of serious unmet need.
Company Info
IPO: 2020-09-18
COMPASS PATHWAYS PLC
3Rd Floor, 1 Ashley Road
Altrincham CHESHIRE WA14 2DT GB
CEO: George Goldsmith
Employees: 166
Phone: 17166766461
COMPASS PATHWAYS PLC / CMPS FAQ
What does CMPS do?
Compass Pathways Plc is a biotechnology company, which provides mental health care services. The company is headquartered in Altrincham, Cheshire and currently employs 166 full-time employees. The company went IPO on 2020-09-18. The firm is engaged in treating mental health conditions focused on rapid and durable responses through the development of its investigational COMP360 psilocybin treatment. COMP360 is its psilocybin formulation that includes its pharmaceutical-grade polymorphic crystalline psilocybin, optimized for stability and purity. The Company’s initial focus is on treatment-resistant depression (TRD), comprising patients who are inadequately served by the current treatment paradigm. The company commenced its Phase III program evaluating its COMP360 psilocybin treatment in TRD. In addition, the Company has ongoing Phase II trials in PTSD and anorexia nervosa. The company also provides support to research institutions conducting investigator-initiated studies with COMP360 psilocybin in areas of serious unmet need.
What is the current price of CMPS stock?
The current stock price of CMPS is 5.79 USD. The price increased by 3.02% in the last trading session.
Does COMPASS PATHWAYS PLC pay dividends?
CMPS does not pay a dividend.
How is the ChartMill rating for COMPASS PATHWAYS PLC?
CMPS has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
What do analysts say about COMPASS PATHWAYS PLC (CMPS) stock?
17 analysts have analysed CMPS and the average price target is 23.77 USD. This implies a price increase of 310.47% is expected in the next year compared to the current price of 5.79.
Can you provide the upcoming earnings date for COMPASS PATHWAYS PLC?
COMPASS PATHWAYS PLC (CMPS) will report earnings on 2026-05-06.